Merck (NYSE:MRK) recently announced the initiation of its Phase 3 EXPrESSIVE clinical trials for MK-8527, a new HIV prevention drug, reflecting its commitment to addressing global health challenges.

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an ...